about
Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like StimulantsMechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease.Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism.[Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortexL-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.Psychostimulant Effect of the Synthetic Cannabinoid JWH-018 and AKB48: Behavioral, Neurochemical, and Dopamine Transporter Scan Imaging Studies in Mice.1-cyclohexyl-x-methoxybenzene derivatives, novel psychoactive substances seized on the internet market. Synthesis and in vivo pharmacological studies in mice.The Cathinones MDPV and α-PVP Elicit Different Behavioral and Molecular Effects Following Acute Exposure.Synthetic cannabinoid JWH-018 and its halogenated derivatives JWH-018-Cl and JWH-018-Br impair Novel Object Recognition in mice: Behavioral, electrophysiological and neurochemical evidence.JWH-018 impairs sensorimotor functions in mice.Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice.Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat.Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway.Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors.Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism.Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study.Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington's disease.Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease.Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex.Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release.Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands.The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine.Stimulation of in vivo dopamine transmission and intravenous self-administration in rats and mice by JWH-018, a Spice cannabinoid.Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease.Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: role of P/Q-type high voltage activated Ca++ channels and endogenous dopamine.Solid lipid nanoparticles as delivery systems for bromocriptine.NR2A and NR2B subunit containing NMDA receptors differentially regulate striatal output pathways.Nociceptin/orphanin FQ modulates motor behavior and primary motor cortex output through receptors located in substantia nigra reticulata.Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway.In vitro evidence for increased facilitation of striatal acetylcholine release via pre- and postsynaptic NMDA receptors in hemiparkinsonian rats.Pharmaco-toxicological effects of the novel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In vitro and in vivo studies.Loss of cortical GABA terminals in Unverricht-Lundborg disease.Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies.
P50
Q26752739-A5C53E91-5458-47FF-A699-78B925A681ADQ34273047-4908850A-EBD5-4D7E-B2AC-E2B128103496Q34300762-A70CA0BE-90C9-4283-804A-BF8F054E90B5Q34337014-FA5BCEBB-E162-4C1C-82E2-8761D3D88B6BQ34769948-C263FD30-D4BA-4917-BDE6-B24A4FF6A5E8Q35044357-E4B11354-9C31-486B-AED0-2F54F7845CE3Q35044849-3DEF4E0C-24D1-46A0-B089-4A03733C02D2Q37486030-70885FF3-9236-43FD-809A-D6631AF8A787Q38616780-6EE29D06-D71D-4F8A-A4CE-5D9A88CD1C92Q38705413-94A15AB7-3C29-4F83-BB53-30CFA9A05510Q38711064-C5F81182-671A-430F-A3B6-A153DF0762A1Q39653751-8AE8CDEF-4EE5-4E13-80F5-CF1858542361Q40926033-E8149C7B-A5AF-4E31-92E2-77331CA9088CQ41227667-1551696E-1481-4FF8-B027-88BEE911C257Q42521959-B5D8FB7C-0C42-4DE2-B576-2D289D01EF0EQ43178103-40FA2499-04C4-4507-B8AD-5C2F9189179FQ43223671-C4533BBB-E9BC-4F7D-AF76-A84CBC323F91Q43281288-1B9AB46B-7A63-47B2-A802-D83D1F3D9A8CQ44299700-8738B313-A21E-4410-875C-71D7DF854099Q44341022-38825E0A-745A-4633-9A94-D8E4E029C9A9Q44535353-2716DFEB-082A-426B-A057-2FD6B5584450Q44553308-F0673AA6-2453-43B2-9700-0400D3051E5BQ44764065-DF2E33A0-E179-4246-82BA-F67CCDAE1699Q44796542-639BCA2E-F796-439C-9786-C6516E66797FQ45177759-10263AFE-35B8-42D2-88A3-553246EAD9DEQ45797407-B3E9AE58-7C50-4837-B372-DCC0F287A707Q46242310-0CB30A65-4FA0-47E7-BCE8-926D83F95E41Q46386584-BACA402A-7128-4971-BF9F-E93C05C006DDQ46676249-4C9334AA-FCCD-4CDF-9496-0A4E7D523826Q46764049-0BBB5855-92B3-4FFE-A97C-022D64C528A7Q46774348-C5ECE457-3FB9-4F79-857E-EAA8A94A38F8Q46825326-7BD95894-B311-4FB5-B9D5-6AE28610E02BQ46912173-44C61C2E-DC82-4C97-A6A9-0FC832B684AFQ47767855-6740AE97-BE02-4223-A104-4B1860726A63Q48243272-43BA82D9-AE0E-4098-BB10-95BE896D00EFQ48279768-1C6E09DE-1F7A-4DF9-9EF2-EC8DCEB77D86Q48292583-A5055330-19A0-49AE-B458-6FF3EE740F0AQ48301733-A5D511B3-464C-475D-9F6F-9E455A43257FQ48546324-B140E23D-D857-404A-BC38-6F5B4593C8A3Q48569237-DAAACA51-4A08-487A-A1C4-06BD20F4CB32
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Matteo Marti
@ast
Matteo Marti
@en
Matteo Marti
@es
Matteo Marti
@nl
Matteo Marti
@sl
type
label
Matteo Marti
@ast
Matteo Marti
@en
Matteo Marti
@es
Matteo Marti
@nl
Matteo Marti
@sl
prefLabel
Matteo Marti
@ast
Matteo Marti
@en
Matteo Marti
@es
Matteo Marti
@nl
Matteo Marti
@sl
P106
P1153
7103082926
P21
P2798
P31
P496
0000-0001-8751-2882